| Autor: |
Stephens LJ; School of Chemistry, Monash University, Clayton, 3800, Australia., Werrett MV; School of Chemistry, Monash University, Clayton, 3800, Australia., Sedgwick AC; Department of Chemistry, The University of Texas at Austin, 105 East 24th Street A5300, Austin, TX 78712-1224, USA., Bull SD; Department of Chemistry, University of Bath, Bath, BA2 7AY, UK., Andrews PC; School of Chemistry, Monash University, Clayton, 3800, Australia.; Center to Impact AMR, Monash University, Clayton, 3800, Australia. |
| Abstrakt: |
As bacteria continue to develop resistance to our existing treatment options, antibiotic innovation remains overlooked. If current trends continue, then we could face the stark reality of a postantibiotic era, whereby routine bacterial infections could once again become deadly. In light of a warning signaled by the WHO, a number of new initiatives have been established in the hope of reinvigorating the antibiotic drug development pipeline. In this perspective, we aim to summarize some of these initiatives and funding options, as well as providing an insight into the predicament that we face. Using clinical trials data, company website information and the most recent press releases, a current update of the antibiotic drug development pipeline is also included. |
